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Abstract
The Noble rat is an established model for studying hormone-induced development of prostatic intraepithelial
neoplasia and prostatic adenocarcinoma. It is known that for a period, hormones in the prostate generate reactive
molecules that have the capacity to overwhelm intracellular defenses, damage macromolecules, and modulate
redox-regulated signaling pathways leading to increased oxidative stress. Such hormone-induced imbalance in
the oxidative stress/antioxidant defense enzymes may lead to neoplastic transformation of the prostate. We inves-
tigated alteration in the expression of critical antioxidant defense enzymes, a redox-regulated transcription factor
nuclear factor κB (NFκB) and its downstream target inflammation-associated cyclooxygenase 2 (Cox-2) in the pros-
tate from hormone-stimulated Noble rats using immunohistochemistry. Further, we also analyzed serum levels of
cytokines and chemokines associated with inflammation using multiplex immunoassay. Our results show that
there was no significant change in the expression of glutathione peroxidase, glutathione S -transferase pi, super-
oxide dismutase, or catalase. However, the level of NADPH quinone oxidoreductase decreased in hormone-
stimulated animals compared with their unstimulated counterparts. Further, the prostate from hormone-stimulated
rats showed very strong expressions of p65, Cox-2, and NFκB DNA binding activity. In addition, the cytokine-
induced neutrophil chemoattractant 2α was significantly upregulated by more than 10-fold (P = .001) in serum
from animals stimulated with hormones. Although further studies are required, we speculate that activation of
NFκB/cytokine-induced neutrophil chemoattractant 2α/Cox-2 along with modulation of antioxidant defense mech-
anisms may create a proinflammatory environment suitable for tumor growth and survival.
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Introduction
Prostate cancer (PCA), the second most common cancer in men, in-
creases with age and is expected to become a major economic burden
for the burgeoning generation of baby boomers in the United States
as life expectancy continues to improve [1]. The incidence of PCA is
highest in western countries compared with that in the Asian pop-
ulation. In addition, when this Asian population migrates to western
countries, the risk increases, indicating that lifestyle, possibly includ-
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ing dietary factors, contributes to the observed high incidence of can-
cer in men in western countries in addition to genetic and epigenetic
factors. Among American men, it is more prevalent in African Amer-
icans than in white Americans [1–3]. Although the exact cause of
PCA is not known, considerable evidence suggests that recurrent
chronic inflammation (CI) plays a critical role in the development
of PCA [4–10]. A direct causal role of CI in PCA development is
not clear; however, morphological changes closely associated with
CI named as postatrophic hyperplasia and proliferative inflammatory
atrophy have been identified in the prostate [11–13]. Such lesions over-
express inflammation-associated gene namely Cox-2. Transcription
factor nuclear factor κB (NFκB) is a major mediator of inflammation,
an activator of cyclooxygenase 2 (Cox-2), and has been shown to be
constitutively overexpressed in prostate tumors [14,15]. Nuclear factor
κB–regulated inflammatory cytokines, such as interleukin 6, are known
to be secreted by prostate. More importantly, epidemiological studies
have observed a reduced incidence of PCA among men using non-
steroidal anti-inflammatory drugs [16]. It has also been shown that
Cox-2–mediated release of prostaglandins induces oxidative damage
[17]. Consistent with this notion, inflammation is frequently present
in prostate biopsies, radical prostatectomy specimens, and tissues
resected for treatment of benign prostatic hyperplasia [6,18]. Inflamma-
tory infiltrates are often found in and around foci of atrophy that are
characterized by increased proliferative index [12]. Further, patients
with symptomatic prostatitis are more susceptible to develop PCA,
and biochemical relapse after radical prostatectomy is more frequent
in patients with high-grade inflammation [19]. These observations sug-
gest that CI and the associatedCox-2 overexpressionmay be early events
in the pathogenesis of “inflammation-related” PCA. Therefore, identi-
fication of factors involved in the development of prostatic intraepithe-
lial neoplasia (PIN) may aid in devising strategies not only to prevent it
but also to prevent its progression to PCA. Besides humans and dogs, the
hormone-induced model of Noble rats is the only system that develops
PIN after hormonal stimulation [20–26]. We investigated alteration in
the expression of critical antioxidant defense enzymes, a redox-regulated
transcription factor NFκB, and its downstream target inflammation-
associated Cox-2 in the prostate from hormone-stimulated Noble rats
using immunohistochemistry. In addition, we have analyzed serum
levels of cytokines and chemokines associated with inflammation using
multiplex immunoassay. Prostate from hormone-stimulated rats
showed very strong expressions of p65, Cox-2, and NFκB DNA bind-
ing activity. In contrast, the expression of the antioxidant defense
enzyme NADPH quinone oxidoreductase (NQO1) was undetectable.
In addition, cytokine-induced neutrophil chemoattractant 2α (CINC-
2α) was significantly upregulated by more than 10-fold (P = .001) in
serum from animals stimulated with hormones. These studies suggest
that activation of NFκB/CINC-2α/Cox-2 along with modulation of
antioxidant defense mechanisms may create a proinflammatory envi-
ronment suitable for tumor growth and survival.
Materials and Methods
Animal Manipulation
Noble rats, 4 to 6 weeks old, purchased from Charles River Lab-
oratories Inc. (Wilmington, MA) were housed in two groups of
10 animals each. Animals were maintained under controlled condi-
tions of 12-hour light-dark cycle and temperature of 23 ± 2°C with
access to food (AIN-93G soy-free diet) and water ad libitum. A group
of 10 animals were implanted with 120-day slow-release hormone
pellets containing 200 mg of testosterone propionate and 25 mg of
17β-estradiol benzoate and another group of 10 animals with pla-
cebo control pellets (Innovative Research America Inc., Sarasota,
FL) at 10 weeks of age. Body weight changes were measured during
the experiment. All the animals were killed at 16 weeks after initia-
tion of hormone treatment. Because the experiment was terminated
by 16 weeks (112 days), we did not change the hormone pellets.
After they were killed, the abdominal cavity was opened, and the
prostate was dissected from the rest of the organs and fixed in
10% buffered formalin. Serial sections were obtained, and histopath-
ologic evaluation was performed.
Histopathology of Prostate Lesions
Serial sections of prostate tissue were stained with hematoxylin and
eosin and evaluated by two independent pathologists (M.S.L. and
M.L.S.) who were blinded to treatment status. We used the extent
of PIN for grading lesions on a scale of 1+ through 3+. Accordingly,
1+ refers to minimal PIN, 2+ moderately extensive, and 3+ wide-
spread PIN.
Nuclear Factor κB DNA Binding Activity
Nuclear factor κB DNA binding activity was measured in nuclear
extracts using TransAM NFκB as described earlier (Active Motif,
Carlsbad, CA) [27]. Extracts were incubated with NFκB consensus
oligonucleotide that was immobilized in a 96-well plate. A primary
antibody specific for an epitope on the bound and active form of
NFκB was added, followed by subsequent incubation with secondary
antibody and developing solution. After incubation, NFκB activity
was measured, colorimetrically, at 450 nm.
Immunohistochemical Analysis
Sections from formalin-fixed, paraffin-embedded blocks of pros-
tate tissue were cut and stained with indicated antibodies as described
earlier [27,28]. The dilutions of the antibodies used were as follows:
p65 and Cox-2 (polyclonal, dilution 1:100, catalog numbers RM1638-
R7 and RM-9121-S0, respectively; Lab Vision/Neomarkers, Fremont,
CA), catalase and superoxide dismutase (SOD) (catalog numbers
AB1877 and 13533, polyclonal, dilution 1:400 and 1 μg/ml, respec-
tively; Abcam, Inc, Cambridge, MA), glutathione S-transferase (GST;
catalog number NB600-326, polyclonal, dilution 1:400; Novus Bio-
logicals, Inc., Littleton, CO), glutathione peroxidase (Gpx; R-171-
100, polyclonal, dilution 1:100;Novus Biologicals), andNQO1 (catalog
number GTx 30636, monoclonal, dilution 1:600; GeneTex, Inc, San
Antonio, TX).
Proliferation and Terminal Transferase dUTP Nick
End-labeling Staining in Tumors
Proliferationwas assessed using the Ki-67 (SP6 antibody; LabVision).
The secondary and tertiary antibodies were a biotinylated link and
streptavidin HRP (Biocare 4 plus Kit; Biocare Medical, Concord,
CA). Apoptosis was assessed using in situ terminal transferase dUTPnick
end-labeling (TUNEL) assay, with biotin-16-dUTP (Roche Applied
Science,Indianapolis, IN) and terminal deoxynucleotidyl transferase
66 NQO1 and CINC-2α in PIN Ghosh et al. Translational Oncology Vol. 2, No. 2, 2009
according to vendor recommendations (Invitrogen, Carlsbad, CA) as we
described earlier [27,28].
Cytokines and Chemokines in Serum
Cytokines and chemokines in the serum were determined using
the Fluorokine MAP Rat Multianalyte Profiling kit (R&D Systems,
Minneapolis, MN) as per the manufacturer’s recommendations.
Blood samples were collected from the animals by cardiac puncture
in serum separator tubes (Becton Dickinson, Franklin Lakes, NJ). Af-
ter centrifugation at 13,000g for 5 minutes, plasma was separated and
stored in aliquots at −80°C for cytokine and chemokine analysis. No
other pretreatment was used.
Statistical Analysis
The grams of body weight measures collected at baseline (intro-
duction of hormone pellets) and at 4-week intervals up to 16 weeks
(time of sacrifice) were analyzed using a mixed-model ANOVA to
test the significance of the interaction between controls and testoster-
one and estradiol (T/E2). Comparisons for PIN measures were per-
formed using Mann-Whitney U tests. Statistical analyses were
performed using SPSS 14.0 software (SPSS, Inc., Chicago, IL), and
group mean differences with P < .05 were considered significant.
Results and Discussion
Changes in the body weight of animals in the course of treatment
with hormones or placebo are shown in Figure 1. Results of mixed-
model ANOVA indicate a significant interaction between treatment
group (F = 17.23, P < .0001) as depicted in Figure 1. The weighted
means for the two groups are not significantly different at baseline
and at 4 and 8 weeks after which the means of body weight for con-
trols are significantly greater than the means for the group treated
with hormones at 12 (P = .0346) and 16 (P < .0001) weeks of
age. Testosterone and estradiol treatment reduced body weight,
which, at 16 weeks, was approximately 20% lower than in the ani-
mals implanted with placebo pellets. Histopathologic analysis was
conducted on prostate tissues obtained from these animals based
on published criteria [20–25]. Prostatic intraepithelial neoplasia
was distinguished from typical hyperplasia based on multiple layers
of dysplastic epithelial cells, which frequently formed alveolar or pap-
illary structures. The increased nuclear size in addition to increased
variability in nuclear shape, chromasia, nucleolar spacing, cell crowd-
ing, and cytoplasmic eosinophilia, which sharply contrasted with the
pale-stained cytoplasm of normal or hyperplastic epithelial cells, were
important criteria for characterizing PIN in Noble rats. A represen-
tative picture showing dorsolateral and ventral prostate is shown in
Figure 2A. All of the animals in the control group that did not receive
hormones were negative for PIN in both the dorsolateral and ventral
prostate (Figure 2A). In the hormone-treated group, 2 of 10 animals
were negative for PIN, whereas 5 of 10 animals showed 1+ PIN grade
and 3 showed 2+ PIN grade in the dorsolateral lobe (Figure 2B). The
results of Mann-Whitney U tests indicate that PIN grades were sig-
nificantly greater for hormone treatment versus control in the dorso-
lateral prostate (P = .0015). Interestingly, we also found higher-grade
PIN in the ventral prostate. Four of 10 animals exhibited 3+ PIN,
2 animals had 2+, and 1 animal had 1+ grade of PIN in the ventral
prostate (P = .0068). Acute inflammation and prominent epithelial
vacuolization accompanied more severe PIN. Acute inflammation
and reactive changes were observed both in the dorsolateral and ven-
tral prostate of animals that were graded 2+ and 3+ PIN; such in-
flammatory changes were not observed in 1+ lesions (Figure 2B).
Testosterone and estradiol have been implicated in the development
of prostatic neoplasia in the Noble rat model [20–25]. Lesions can also
be induced by chemical carcinogens such as methylnitrosourea and
3,2′-dimethyl-4-aminobiphenyl. When testosterone is given either
alone or with estrogens, invasive carcinomas have been found in the
dorsolateral and anterior prostate, regardless of the rodent strain [23].
In our study, PIN occurred only in hormone-treated rats, consistent
with published reports [20–26]. In addition, we show induction of
PIN in the ventral prostate in response to hormonal stimulation in
Noble rats. Although it has been shown that the rats stimulated with
testosterone and estradiol develop extensive multifocal epithelial dys-
plasia and invasive adenocarcinoma specifically in the dorsolateral pros-
tate, exposure of animals to testosterone plus diethylstilbestrol causes
development of atypical hyperplasia or dysplasia in a vacuolarized
epithelium and carcinoma in situ in the ventral prostate but not in
the dorsolateral prostate [29,30]. We believe that the induction of
PIN in the ventral prostate could be due to the method of infusion
of hormones into the body cavity because we used slow-release hor-
mone pellets implanted under the skin in contrast to sialistic tubes
used by other investigators to deliver these hormones [20–25]. Fur-
thermore, hormones may indirectly influence prostate carcinogenesis
in the ventral prostate through accumulation of mast cells and macro-
phages selectively in the ventral prostate as previously suggested [31].
Transgenic mice overexpressing prostate-specific Akt also develop PIN
lesions specifically in the ventral prostate [32]. Nonetheless, it has been
shown that exposure of Fisher 344 rats to dietary 2-amino-1-methyl-6-
phenylimidazo[4,5-b]pyridine for 20 weeks results in the development
of localized invasive prostatic carcinomas in the ventral prostate after
52 weeks [33]. It is not clear whether the development of PIN lesions
in this model is due to alteration of hormonal milieu because it has
been shown that estrogen receptor β plays a role in prostate carcino-
genesis [34]. Recently, it has been shown that morphological changes
Figure 1. Mean body weight of Noble rats. Noble rats, 8 to
10 weeks old, were implanted with T/E2 as described in the
Materials and Methods section. Animals were observed for body
weight changes throughout the study (16 weeks). Mean body
weight in each experimental group ± SD as a function of time is
shown in weeks.
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Figure 2. Histopathologic analysis of prostate. Hematoxylin and eosin evaluation was conducted by two independent pathologists (M.S.L.
and M.L.S.) as described in the Materials and Methods section. (A) A representative picture at a magnification ×100 from animals without
and with hormone stimulation. Prostates from animals without hormonal stimulation show uniform layer of cells with small nuclei and no
nucleoli, whereas animals stimulated with hormones show histological changes associated with PIN. Multiple cell layers, enlarged nuclei,
nucleoli, vacuolar changes, clear vesicles, and decreased secretory material are present. (B) Graphical representation of PIN formation.
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in the Noble rat model induced by T/E2 involve appearance of inflam-
matory PIN-like lesions followed by microscopic adenocarcinomas
[35]. Further, this study also demonstrated the importance of contin-
uous high concentrations of T/E2 for prostate carcinogenesis [35]. It
seems that PIN lesions in the dorsolateral prostate do not progress to
adenocarcinomas, whereas lesions in the periurethral area progress to
adenocarcinomas [35].
The observed development of PIN could be due to increased pro-
liferation, decreased apoptosis, or alteration in the expression of
inflammation-associated genes such as NFκB and downstream ef-
fectors such as Cox-2 [36,37]. In addition, intracellular prooxidant/
antioxidant balance has been shown to be influenced by hormone
stimulation of Noble rats [38]. Further, hormones may contribute
to the induction of oxidative stress in rat prostate gland in vivo by
modulating levels and activities of antioxidant enzymes [39]. In an
attempt to decipher the mechanism of hormone-induced inflamma-
tion and PIN development, we evaluated the expression of Ki-67
(proliferation indicator), apoptosis (TUNEL staining), p65 (NFκB
signaling molecule), and Cox-2 (a downstream target of NFκB in-
volved in inflammation) using immunohistochemical analysis in three
representative prostate samples from each group. As shown in Figure 3,
the expression of Ki-67 was higher in the prostate from hormone-
stimulated rats compared with that from placebo group animals. We
also found that Ki-67 was higher in the hormone-treated animals with
inflammation including the stromal part. There was no significant
change in apoptosis compared with unstimulated animals suggesting
that the balance between proliferation and apoptosis is disrupted on
hormone stimulation.
Expression of both p65 and Cox-2, an inflammation-associated
gene, was very strong in the dorsolateral and ventral prostate from
hormone stimulated rats. In contrast, prostate tissue of unstimulated
rats showed a low level of Cox-2 immunoreactivity (Figure 3). It is well
established that Cox-2 is regulated by transcription factor NFκB.
Nuclear factor κB has been shown to regulate a wide variety of genes
involved in cell proliferation, survival, migration, tumorigenesis, and
metastasis [36]. Accordingly, we observed significantly higher levels of
NFκB DNA binding activity in extracts prepared from prostate tissue
of hormone-treated animals compared with that of the placebo group
(Figure 4). These data implicate a potential role for the activation of
NFκB signaling pathway and its downstream target Cox-2 in response
to hormone stimulation in the Noble rat model. Given both NFκB
and Cox-2 are associated with inflammatory changes, activation of this
signaling may lead to the development of inflammation in the ventral
prostate. How such inflammatory changes lead to cancer remains
largely unknown.
Figure 3. Proliferation, TUNEL, and immunohistochemical analysis of representative prostate tissue from control and hormone-stimulated
Noble rats: paraffin-embedded tissues sections were stained with Ki-67 to assess proliferation, p65, and Cox-2. Negative controls were
included by omitting the primary antibody. Increased expression of Ki-67, p65, and Cox-2 can be seen in the prostate from hormone-
stimulated rats. There was no significant difference in the TUNEL-positive cells between unstimulated and hormone-stimulated rats.
Figure 4. Modulation of NFκB DNA binding activity in prostate
from unstimulated and hormone-stimulated nuclear extracts:
NFκB DNA binding activity was measured in nuclear extracts pre-
pared from unstimulated and hormone-stimulated rats (three ani-
mals for each sample) by using TransAM NFκB (Active Motif).
Increased NFκB DNA binding activity can be seen in the prostate
from hormone-stimulated rats.
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Because chemokine network is activated by inflammation, we in-
vestigated the presence of various cytokines and chemokines in serum
from these animals using multiplex immunoassay as described in
methods [40]. Analysis of these data indicated nonsignificant altera-
tions in the serum levels of most of the cytokines and chemokines
measured in response to hormone stimulation. However, we saw sig-
nificant (10-fold; P = .001) up-regulation of cytokine-induced neu-
trophil CINC-2α in serum from animals stimulated with hormones
(Figure 5). Cytokine-induced neutrophil chemoattractant 2α is a
counterpart of the human growth-regulated oncogene product that
has been shown to be vital for cell survival and malignant transfor-
mation and activated by RAS [41]. Growth-regulated oncogene 1 has
also been shown to be present in higher levels in serum samples from
women with ovarian cancer [40]. Both protein and mRNA levels of
CINC-2α are upregulated in gastric mucosa cells in response to tumor
necrosis factor α [42]. Although we do not know how CINC-2α is
involved in prostate carcinogenesis, these studies implicate a potential
role for CINC-2α in inflammation-mediated prostate tumorigenesis.
In addition, the observed hormone-induced pathological changes
could be due to changes in the levels and activities of antioxidant
enzymes in the prostate [39]. We used immunohistochemistry to
analyze prostate tissue for expression of critical enzymes involved in
antioxidant defense including catalase, Gpx, glutathione S -transferase
pi (GSTpi), SOD, and NQO1 immunohistochemically. We did not
find any significant changes in the expression of catalase, Gpx, GSTpi,
or SOD. However, the expression of NQO1 was lost in the prostate
from hormone-stimulated rats when compared with the prostate from
unstimulated rats (Figure 6). NADPH quinone oxidoreductase is an
important biotransformation enzyme that has been implicated in pro-
tecting cells from oxidative stress and against carcinogenesis [43–45].
Consistent with this notion, loss of NQO1 in hormone-stimulated rats
may sensitize the prostatic epithelium to the observed pathological
Figure 5.Modulation of inflammatory cytokines and chemokines in
the serum from unstimulated and hormone-stimulated rats: Cyto-
kines and chemokines in the serum from five different animals from
each group were determined using the Fluorokine MAP Rat Multi-
analyte Profiling kit (R&D Systems) as per the manufacturer’s re-
commendations. Data are presented in picograms per milliliter as
average ± SD, and the statistical significance of the data was ana-
lyzed by Student’s t test. Significant up-regulation of CINC-2α can
be seen in the serum from hormone-stimulated rats.
Figure 6. Modulation of catalase, Gpx, GSTpi, SOD, and NQO1
in the prostate from unstimulated and hormone-stimulated rats:
Paraffin-embedded tissue sections were stained with the indicated
antibodies. Loss of NQO1 expression can be seen in the prostate
from hormone-stimulated rats with no significant differences in the
immunoreactivity to catalase, Gpx, GSTpi, or SOD. Negative con-
trols were included by omitting the primary antibody. Hematoxylin
and eosin (H&E) evaluation on the same slide is also shown.
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changes. However, detailed studies need to be done to demonstrate the
role of NQO1 in prostate tumorigenesis.
Data presented in this paper identify activation of 1) NFκB signal-
ing (evidenced by increased p65 expression, NFκB DNA binding
activity, and its downstream target gene Cox-2), 2) CINC-2α, and
3) loss of NQO1 (antioxidant defense enzyme) in the prostate from
hormone-stimulated rat prostate. Prostatic intraepithelial neoplasia is
induced by hormone treatment without the need of a carcinogen to
initiate the neoplastic process in a manner similar to the human
tumorigenesis. Therefore, the induction of PIN and associated in-
flammatory changes in Noble rats after hormone treatment simulates
a potential mechanism of PCA development in man, where hormonal
factors are predominantly involved. These studies suggest that activa-
tion of NFκB/CINC-2α/Cox-2 along with modulation of antioxidant
defense mechanisms may create a proinflammatory environment suit-
able for tumor growth and survival. However, more detailed studies
including silencing approaches are required to demonstrate how mod-
ulation of CINC-2α, NQO1, and NFκB can affect the formation of
PIN as well as connection between inflammation and PCA.
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